Status:
COMPLETED
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
70+ years
Phase:
PHASE4
Brief Summary
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer. Patients will be randomized to receive ...
Eligibility Criteria
Inclusion
- Adult patients, \>=70 years of age
- Non-small cell lung cancer
- Naive to prior chemotherapy or specific immunotherapy
- Presence of at least 1 measurable lesion
Exclusion
- Active non-controlled infection or disease
- CNS metastases
- Any other malignancies (other than adequately treated basal cell cancer of skin, or in situ cancer of the cervix)
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT01196078
Start Date
February 1 2007
End Date
December 1 2010
Last Update
July 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei, Taiwan